Prostate Cancer
Conditions
Brief summary
Prostate cancer is the most common cancer among men 50 years and older and mainly affets patients 75 years old. Androgen deprivation therapy is indicatated in intermediates and high risks form of prostate cancer, in association with radiotherapy for 6 monts to 3 years. It is also indicated after surgery. Current therapies induce inhibition of sexual hormones as androgens among which testosterone. These therapies present side effects which have to be acknowledeged during the elaboration therapeutic startegies in older patients: hypogonadism induced by androgen deprivation therapy (ADT) causes loss of bone mineral density, diminution of lean body mass and increase of fat body mass. Sarcopenia is defined by a loss of muscle strength associated to a decrease in skeletal muscle mass. In addition to aging, many factors may contribute to sarcopenia as cancer and/or ADT. This cohort study aims to evaluate risk factors associated to sarcopenia prevalence and the relationship between ADT and sarcopenia incidence, in patients 70 years or older with localized or locally advanced prostate cancer
Interventions
OTHERPrevalence of sarcopenia in older patient with prostate cancer
All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 70 years and older * Proven localized or locally advanced prostate cancer * Treated by radiotherapy associated to ADT * CGA needed (screened by G8 Score ≤14)
Exclusion criteria
* Protected pateint under guardiaship * Metastatic prostate cancer * Patient refusal * Patient cripled with severe dementia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of sarcopenia in older patient with prostate cancer | 36 months | All patients are screened for sarcopenia with the SAR-F questionnaire test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of sarcopenia severity | 36 months | The severity of the sarcopenia will be measured by the evaluation of the physical performances |
| Skeletal Muscular Index | 36 months | Sarcopenia prevalence measuring Skeletal Muscular Index (SMI= Appendicular skeletal muscle mass/height²) using dual-energy X-ray absorptiometry (DXA) |
Countries
France
Contacts
STUDY_DIRECTOREmilie Garrido-Pradalié
Assistance Publique Hôpitaux de Marseille
Outcome results
None listed